PT - JOURNAL ARTICLE AU - Gui, Gege AU - Dillon, Laura W. AU - Ravindra, Niveditha AU - Hegde, Pranay S. AU - Andrew, Georgia AU - Mukherjee, Devdeep AU - Wong, Zoë AU - Auletta, Jeffery AU - Chaer, Firas El AU - Chen, Evan AU - Chen, Yi-Bin AU - Corner, Adam AU - Devine, Steven M. AU - Iyer, Sunil AU - Jimenez Jimenez, Antonio Martin AU - De Lima, Marcos J.G. AU - Litzow, Mark R. AU - Kebriaei, Partow AU - Spellman, Stephen R AU - Zeger, Scott L. AU - Page, Kristin M. AU - Hourigan, Christopher S. TI - Measurable Residual <em>IDH1</em> before Allogeneic Transplant for Acute Myeloid Leukemia AID - 10.1101/2023.07.28.23293166 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.28.23293166 4099 - http://medrxiv.org/content/early/2023/08/01/2023.07.28.23293166.short 4100 - http://medrxiv.org/content/early/2023/08/01/2023.07.28.23293166.full AB - Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. The persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoetic cell transplant (alloHCT) has been established as associated with increased relapse and death after transplant. The prognostic implications of persistence of other common AML-associated mutations, such as IDH1, at this treatment landmark however remains incompletely defined. We performed testing for residual IDH1 variants (IDH1m) in pre-transplant CR1 blood of 148 adult patients undergoing alloHCT for IDH1-mutated AML at a CIBMTR site between 2013-2019. No post-transplant differences were observed between those testing IDH1m positive (n=53, 36%) and negative pre-transplant (overall survival: p = 0.4; relapse: p = 0.5). For patients with IDH1 mutated AML co-mutated with NPM1 and/or FLT3-ITD, only detection of persistent mutated NPM1 and/or FLT3-ITD was associated with significantly higher rates of relapse (p = 0.01). These data, from the largest study to date, do not support the detection of IDH1 mutation in CR1 blood prior to alloHCT as evidence of AML MRD or increased post-transplant relapse risk.Competing Interest StatementHourigan: The National Heart, Lung, and Blood Institute receives research funding for the laboratory of Dr. Hourigan from the Foundation of the NIH AML MRD Biomarkers Consortium. Auletta: Advisory Committee: AscellaHealth and Takeda El Chaer: Consultant: SPD Oncology, Amgen, Association of Community Cancer Centers; Clinical Trial Grant Support (PI) to the University of Virginia: Amgen, BMS, Celgene, SPD Oncology, Sanofi, Bristol Myers Squibb, FibroGen, PharmaEssentia, BioSight, MEI Pharma, Novartis, Arog pharmaceuticals; Travel grant: DAVA Oncology E Chen: Consultant: Rigel Pharmaceuticals and AbbVie Corner: Employment: Bio-Rad Laboratories Jimenez Jimenez: Funding: Abbvie De Lima: Advisory Board: Pfizer, Bristol Myers Squibb; Data Safety Monitoring Board: Novartis, Abbvie; Research Funding: Miltenyi Biotec Kebriaei: Consultant: Pfizer, Jazz PharmaceuticalsFunding StatementThis work was supported in part by the Intramural Research Program of the National Heart, Lung, and Blood Institute and by the National Institutes of Health Director's Challenge Innovation Award, and the Foundation of the NIH AML MRD Biomarkers Consortium.. The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 and U24HL157560 from NHLBI and NCI; U24CA233032 from the NCI; OT3HL147741 and U01HL128568 from the NHLBI; HHSH250201700005C, HHSH250201700006C, and HHSH250201700007C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2832 and N00014-21-1-2954 from the Office of Naval Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients provided written informed consent to participate in the Center for International Blood and Marrow Transplant Research research protocol, which was approved by the National Marrow Donor Program institutional review board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw FASTQ files are the NCBI Sequencing Reads Archive (SRA) (Accession: PRJNA834073 and PRJNA997373).